Targets › GHRHR
1 program from 1 company in 2 trials: 2 Phase 2; Gastroenterology, Infectious disease; next expected readout Feb 2027.
Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion. (UniProt, Q02643)
Open in Phaseline: the race on GHRHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hudson Biotech | Tesamorelin Growth hormone-releasing hormone receptor agonist | GHRHR | Phase 2 | Metabolic Associated Steatotic Liver Disease; HIV-1-infection | Feb 2027 |
Metabolic Associated Steatotic Liver Disease (1) HIV-1-infection (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.